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We cloned a full-length mouse cDNA and its human
omologue encoding a novel protein designated as
SR-25.” In Northern blot analysis, SR-25 mRNA was
xpressed in all organs tested, and relatively abun-
ant in testis and thymus. Deduced amino acid se-
uences of mouse SR-25 and human SR-25 showed
7.7% identity. SR-25 has a serine-arginine repeat (SR
epeat) and two types of amino acid clusters: a serine
luster and a highly basic cluster. Based on the pres-
nce of many nuclear localizing signals and a similar-
ty to RNA splicing proteins, SR-25 is strongly sug-
ested to be a nuclear protein and may contribute to
NA splicing. © 2000 Academic Press
To obtain a novel cDNA clone from the mouse pan-
reatic b-cell line, MIN6, we constructed a cDNA li-
rary from mRNA of MIN6 cells, and randomly se-
uenced 1,173 clones from their 39 ends (1). The
btained sequences were compared with each other at
rst to assess the frequency of their appearance in our
ibrary, and then with the DNA data base in GenBank
sing a FASTA program. There are 898 independent
lones in the whole 1,173 clones. Out of the 898 clones,
00 clones were unknown. Among them, we encoun-
Abbreviations used: FBS, fetal bovine serum; ORF, open reading
rame; RACE, rapid amplification of cDNA ends; RT, reverse tran-
criptase; snRNP, small nuclear ribonucleoprotein particle; SR re-
eat, serine-arginine repeat; TdT, terminal deoxynucleotidyl trans-
erase.
1 Sequence data from this paper have been submitted to the DDBJ/
MBL/Genbank databases with the Accession Nos. AB035383 and
B035384.
2 To whom correspondence should be addressed at Division of
enetic Information, Institute for Genome Research, University of
okushima, Tokushima, 770-8503, Japan. Fax: 181-88-631-9476.
-mail: itakura@nutr.med.tokushima-u.ac.jp.444006-291X/00 $35.00
opyright © 2000 by Academic Press
ll rights of reproduction in any form reserved.uences. From deduced amino acid sequence, the
DNA is thought to be encoding a nuclear protein, and
t was designated as SR-25.
ATERIALS AND METHODS
Cultured cell lines. Human insulinoma cells dispersed and cul-
ured for 10 passages were used as the sourse of human islet b cells.
IN6 and NIT-1 were derived from mouse insulinomas, whereas
-TC1 originated from a mouse a-cell tumor. QGP-1 was derived
rom a human pancreatic endocrine tumor, and AR42J was from a
at pancreatic exocrine tumor. AtT20 and a-TSH were from a mouse
ituitary tumors, and GH3 was from a rat pituitary tumor. PC12 was
rom a rat pheochromocytoma. NIH/3T3 and TIG-1 were from mouse
nd human fibroblasts, respectively.
Cloning of mouse SR-25 cDNA. MIN6 cDNA library was con-
tructed as described previously (1). The fragment (740 bp) of mouse
R-25 cDNA was obtained from the random sequencing of this li-
rary. To obtain the full-length cDNA, rapid amplification of cDNA
nds (RACE) (2) was performed for both 39 and 59 terminal regions.
39 RACE. Total RNA (5 mg) purified from MIN6 cells with
SOGEN (Nippongene, Tokyo, Japan) was reverse-transcribed to
DNA with a SuperScript Preamplification System for First Strand
DNA Synthesis kit (Gibco BRL, Rockville, MD) using an oligo-dT
rimer. Using the first-strand cDNA as a template, nested PCR was
erformed. For the first PCR, a gene-specific primer (59GTGCAGT-
GATTGGACAG39) and a (dT)17-adaptor primer (59GACTCGAGTC-
ACATCGATTTTTTTTTTTTTTTTT39) were used. For the second
CR, a gene-specific primer (59ATTGGACAGCAGAGTGTCAC39)
nd an adaptor primer (59CCGACTCGAGTCGACATCG39) were
sed. PCR conditions used in this study were as follows: initial
enaturation at 95°C for 2 min, 35 cycles of 95°C for 1 min, 60°C for
min, and 72°C for 2 min, and the final extention at 72°C for 10 min.
59 RACE. Total RNA (5 mg) extracted from MIN6 cells was
everse-transcribed to the first-strand cDNA with a gene-specific
rimer (59GTTGAACTGGATCGCGATGT39). After ethanol precipi-
ation, the pellet was dissolved in 30 ml of H2O and denatured at
5°C for 3 min. To extend poly(dA) from 39 end of the first-strand
DNA, it was incubated in 100 mM sodium cacodylate buffer (pH 7.2)
ontaining 1 mM CoCl2, 0.1 mM DTT, 2 mM dATP and 10 U of
erminal deoxynucleotidyl transferase (TdT) (Takara, Tokyo, Japan)





















































































Vol. 269, No. 2, 2000 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONSin. Using the first-strand cDNA accompanied by poly(dA), nested
CR was performed. For the first PCR, the sense (dT)17-adap-
or primer described above and a gene-specific antisense primer
59GTTGAACTGGATCGCGATGT39) were used; for the second PCR,
he sense (dT)17-adaptor primer and a gene-specific antisense primer
59TTGTGGCCCTGGGATCTGGAG39) were used; and for the third
CR, a sense (dT)3-adaptor primer (59ATCGACTCGAGTCGACATC-
ATTT39) and a gene-specific antisense primer (59TGCTTGCT-
CTCTCCTCAAC39) were used. To ascertain the continuity of cDNA
ragments obtained from MIN6 cDNA library and obtained with 39
nd 59 RACE, the full-length mouse SR-25 cDNA was amplified at a
tretch by PCR using the first-strand cDNA as a template with a
ense primer (59CCTGCTGTGGGCTAATGGTG39) and an antisense
rimer (59TCCAATCCACTGCACCCAAG39).
Cloning of human SR-25 cDNA. The cloning strategy is shown in
ig. 1. At first, 39 RACE was carried out. Total RNA (5 mg) purified
rom a human insulinoma cell line was reverse-transcribed to first-
trand cDNA with an oligo-dT primer. The first PCR of nested PCR
as performed with a primer for mouse SR-25 cDNA (P1: 59GCCT-
CCAGATGCGAACAGG39) and the (dT)17-adaptor primer (Pa:
9GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT39); the sec-
nd PCR was performed with a primer for mouse SR-25 cDNA (P2:
9CGACAGAGCGTTATTCGAAG39) and the adaptor primer (Pb:
9CCGACTCGAGTCGACATCG39); and the third PCR was per-
ormed with a primer for mouse SR-25 cDNA (P3: 59CGTAACCAAA-
AACGACACA39) and the (dT)3-adaptor primer (Pc: 59ATCGACTC-
AGTCGACATCGATTT39). The obtained 39 fragment of human
R-25 cDNA was sequenced and two antisense primers specific to
his sequence (P5: 59GAGAAGAGACTGGGCTGGG39 and P6:
9AGACCAATCCACGGGGGAAA39) were prepared. Using these an-
isense primers and a sense primer for mouse SR-25 cDNA (P4:
9TCCAGATCCCAGGGCCACAA39), semi-nested PCR was carried out.
The obtained human SR-25 cDNA fragment (approximately 500
p) was sequenced and four antisense primers specific to this se-
uence (P7: 59TGCTGTGCTTCCGCCTTCTC39, P8: 59AGGAGCTA-
AAGAACTGGAAG39, P9: 59GCAGTTCCTCGAGGTGTCTTTC39,
nd P10: 59TTTCTCTTTTCCGACCCCCG39) were prepared for 59
ACE. Total RNA (5 mg) extracted from human insulinoma cell line
as reverse-transcribed with P7, and poly(dA) was added to 39 end of
rst-strand cDNA by TdT as well as 59 RACE for mouse SR-25 cDNA.
sing the first-strand cDNA with poly(dA), nested PCR was per-
ormed. For the first, second, and third PCR, the following primer
ets were used respectively: Pa vs. P8, Pb vs. P9, and Pc vs. P10. To
scertain the continuity of obtained cDNA fragments, the full-length
uman SR-25 cDNA was amplified at a stretch by PCR using the
rst-strand cDNA as a template with a primer set specific to human
R-25 cDNA (59CCTGCTGTGGGCTAATGGTG39 and 59TCCAATC-
ACTGCACCCAAG39).
Sequence analyses. Nucleotide sequence was determined by dye
rimer or dye terminator cycle sequencing using a Model 377 DNA
equencer (PE Biosystems, Foster City, CA). Sequence homology and
ydrophilicity of mouse and human SR-25 were analyzed by
Genetyx ver 8.0” (Software Development Co., Ltd., Tokyo, Japan).
he open reading frame (ORF) of SR-25 cDNA was detected by “ORF
nder” which is a computer program available at http://www.
cbi.nlm.nih.gov/gorf/gorf.html. A homology search of the deduced
mino acid sequence was analyzed by “FASTA” at http://crick.
enes.nig.ac.jp/homology/fasta-e.html. To detect sorting signals of
R-25 and to predict its subcellular localization, “Prediction of the
ubcellular Location of Proteins by Neural Networks” at http://
redict.sanger.ac.uk/nnpsl/ (3) and “PSORT” at http://psort.nibb.
c.jp:8800/ (4) were used.
Southern blot analysis. Mouse genomic DNA fragments (5 mg)
igested with restriction enzymes were separated by electrophoresis
n a 1% agarose gel, and transferred onto a nylon membrane (Gene-445creen Plus; NEN Research Products, Boston, MA). Mouse full-
ength SR-25 cDNA (1,100 bp) was radiolabeled with [a-32P]-dCTP
3,000 Ci/mmol, Amersham, Buckinghamshire, U.K.) using a Mega-
rime DNA Labeling System (Amersham), and used as a probe. DNA
n the membrane was hybridized to the probe in a mixture of 50%
ormamide, 10% dextran sulfate, 1% SDS, and 100 mg/ml salmon
perm DNA at 42°C for 16 h. The membrane was washed three times
ith 0.2 3 SSC at 50°C for 30 min.
Northern blot analysis. Total RNA isolated with ISOGEN
Nippongene) was electrophoresed on a 1.0% agarose gel with 2%
ormaldehyde, and transferred onto nylon membrane. The same
robe as Southern blot analysis was used. Hybridization was carried
ut in 5 3 SSPE containing 50% formamide, 0.1% SDS, 100 mg/ml
almon sperm DNA, and a radiolabeled probe at 42°C for 16 h. The
embrane was washed three times with 2 3 SSPE, 1 3 SSPE, and
.1 3 SSPE 1 0.1% SDS, in turn, at 65°C for 30 min.
Cell cycle analysis. To examine whether SR-25 expression is cell
ycle-dependent, TIG-1 fibroblasts synchronized in the G0 phase by
erum deprivation (0.5% FBS) for 48 h were released with 10% FBS
rom cell arrest, and total RNA was extracted from TIG-1 cells at 0,
2, 18, 24, 30, and 36 h after serum stimulation for Northern blot
nalysis.
ESULTS AND DISCUSSION
ucleotide Sequences of Mouse and
Human SR-25 cDNAs
Full-length sequences of mouse and human SR-25
DNAs are shown in Figs. 2 and 3, respectively. Their


























Vol. 269, No. 2, 2000 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONSRFs were considered to be from nucleotide number
39 to 1,028 for mouse SR-25 cDNA (Fig. 2), and from
ucleotide number 63 to 719 for human SR-25 cDNA
Fig. 3), respectively. The reasons why these ORFs
ere determined are as follows: Peptide chains trans-
ated in other frames were too short to function; “ORF
nder” indicated that these ORFs were most feasible;
ucleotide sequence identity between mouse and hu-
an SR-25 cDNAs was higher in these ORFs (79.0%)
han those in both 59 (50.0%) and 39 (54.7%) flanking
egions, which are putative non-coding regions; and
he sequence around the ATG initiator codon of human
FIG. 2. The cDNA sequence and deduced amino acid sequence
5 5, SR repeat; - - -, serine cluster; —, basic cluster; and *, stop c446R-25 cDNA (GCCATGG) was compatible with Kozak
equence for efficient ribosome binding and protein
ranslation (5). Kozak reported that a purine nucleo-
ide (A or G) in position 23, i.e., 3 nucleotides upstream
rom the ATG codon, has a dominant effect for initia-
ion by eukaryotic ribosomes. Although the sequence
urrounding the ATG start codon of mouse SR-25
DNA (CTGATGG) does not have the purine nucleotide
n position 23, it has G in position 14 as well as
uman SR-25 cDNA. The G at 14 was also reported to
e important for the efficient ribosome binding next to
he purine nucleotide at 23 (5).


































Vol. 269, No. 2, 2000 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONSmino Acid Sequences of Mouse SR-25 and
Human SR-25
Deduced amino acid sequences of mouse SR-25 and
uman SR-25 showed 77.7% identity (Fig. 4). Both
roteins have three kinds of highly conserved amino
cid motifs, i.e. a serine/arginine repeat (SR repeat), a
erine cluster, and a basic cluster. Hydrophilicity anal-
sis indicated that SR-25 is a highly hydrophilic pro-
ein, and its pattern for mouse SR-25 was very similar
o that for human SR-25 (Fig. 5). In both mouse SR-25
nd human SR-25, 28% of amino acid composition was
asic amino acids (lysine and arginine) with calculated
I of 11.7 for mouse SR-25, and 11.4 for human SR-25.
olecular weights of mouse and human SR-25 were
5,525 Da and 24,629 Da, respectively.
By analysis with “Prediction of the Subcellular Lo-
ation of Proteins by Neural Networks”, the probability
FIG. 3. The cDNA sequence and deduced amino acid s447hat SR-25 is localized in the nucleus was estimated at
1.9% for both mouse and human SR-25. Similarly,
PSORT” predicted that SR-25 is a nuclear protein
t the probabilities of 82.6% for mouse SR-25 and
8.3% for human SR-25. According to these two
omputer programs, basic clusters (RKKRAKHKE-
KRKKKKKKRKKKLKKRVKEK for mouse SR-25
nd RKKRGKYKDKRRKKKKKRKKLKKKGKEK for
uman SR-25) are putative nuclear targeting signals.
ndeed, a cluster of several basic amino acid residues in
roteins has been shown to be a signal required for
uclear import by an interaction with positively-
harged portions of the nuclear pore complex: for ex-
mple, KRPRP for adenovirus E1a protein (6) and
KKKRKV for SV40 virus large T antigen (7). How-
ver, the basic clusters of mouse SR-25 and human
R-25 appear to be too long for only nuclear transport.









































Vol. 269, No. 2, 2000 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONSn general, a longer basic cluster than nuclear target-
ng signals was necessary for targeting to nucleolus,
uch as PKTRRRPRRSQRKRPPTP for HTLV-1 rex
rotein (8), RQARRNRRRRWRERQR for HIV-1 virus
ev protein (9), GRKKRRQRRRAHQN for HIV-1 virus
at protein (10), KRKKEMANKSAPEAKKKK for
ucleolin (11), and SKRLSSRARKRAAKRRLG for
120 nucleolar protein (12). Therefore, SR-25 may be
ransported to nucleolus in which rRNA is synthesized.
n addition to the nuclear targeting signal, highly basic
omains of nuclear proteins often function as binding
ites to the phosphate backbone of DNA (13–15) and
NA (16, 17).
SR-rich domain is a characteristic feature of pre-
RNA splicing factors such as small nuclear ribonu-
leoprotein particles (snRNPs) (18) and non-snRNP
plicing factors containing SR repeats (SR proteins)
19). These splicing factors are required for constitu-
ive pre-mRNA splicing and they also regulate al-
ernative splice site selection in a concentration-
ependent manner (20, 21). Their SR-rich domains
nteract with each other and many splicing factors
ssemble into the splicing complex (22–24). Further-
ore, SR-rich domains of some splicing factors are
hosphorylated with serine kinases (25, 26), leading to
he disassembly of splicing factors. Through the SR
epeat, SR-25 may participate in the splicing complex.
It is difficult to predict the function of a serine cluster
n SR-25, because the serine cluster plays different
oles in individual proteins. It can also be phosphory-
ated by serine kinases, resulting in a conformational
FIG. 4. Sequence alignment of mouse SR-25 and human SR-25.
dentical and similar amino acids are indicated by asterisks and
ots, respectively.448hange of the protein structure. Like SR-25, human
NPS1 which is a general activator of pre-mRNA splic-
ng, also has an extensive serine-rich domain (27).
outhern Blot Analysis
Because the genomic sequence of mouse SR-25 has a
amHI site (data not shown), two BamHI fragments
ere detected in Southern blot analysis (Fig. 6, lane 1).
FIG. 5. Hydrophilicity analysis of mouse SR-25 (A) and human
R-25 (B).
FIG. 6. Southern blot analysis of mouse genomic DNA. Restric-
ion enzymes used are as follows: lane 1, BamHI; lane 2, EcoRI; lane
















































Vol. 269, No. 2, 2000 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONSingle bands observed in other lanes indicate that
R-25 gene exists as a single copy per haploid in the
ouse genome.
orthern Blot Analysis
Because SR-25 cDNA was originally cloned from a
ouse insulinoma cell line (MIN6), SR-25 mRNA ex-
ression was examined mainly in several endocrine
ells (Fig. 7A). The major transcript for SR-25 was
etected at 1.5 kb and several minor transcripts were
round 5.0 kb. SR-25 mRNA was relatively abundant
n pancreatic islets, MIN6, NIT-1, a-TC1, AtT-20, and
IH/3T3, whereas its level was relatively low in GH3,
C12, QGP-1, and a-TSH. Only in AR42J cells, SR-25
RNA expression was not detected.
Organ distribution of SR-25 mRNA was also exam-
ned (Fig. 7B). It was expressed in all organs tested,
nd relatively abundant in testis and thymus. X16/
Rp20, which is a splicing factor, is also strongly ex-
FIG. 7. Northern blot analysis. (A) Cell lines. Lane 1, pancreatic
slet; lane 2, MIN 6; lane 3, NIT-1; lane 4, a-TC1; lane 5, AR42J; lane
, AtT-20; lane 7, GH3; lane 8, NIH/3T3; lane 9, PC12; lane 10,
GP-1; and lane 11, a-TSH. (B) Mouse organs. Lane 1, pancreas;
ane 2, MIN6; lane 3, brain; lane 4, heart; lane 5, intestine; lane 6,
idney; lane 7, liver; lane 8, muscle; lane 9, ovary; lane 10, spleen;
ane 11, stomach; lane 12, testis; and lane 13, thymus.449est that SR-25 expression is associated with X16/
Rp20 expression, and that it may be correlated
ith cell proliferation/differentiation (29–31). Thus,
hether the level of SR-25 expression changes in a cell
ycle-dependent manner was examined using TIG-1
broblasts, which have been used for cell cycle analysis.
he level of SR-25 mRNA standardized for 28S rRNA did
ot obviously change in TIG-1 cells (data not shown).
Taken together, this novel protein, SR-25, is strongly
uggested to be localized in the nucleus and may inter-
ct with RNA splicing factors.
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